The U.S. Food and Drug Administration (FDA) expects a nationwide shortage of Adderall and Adderall IR to extend through the end of the year, following manufacturing delays by the largest producer of Adderall in the country, Teva Pharmaceuticals LLC.
Other manufacturers continue to produce amphetamine mixed salts but not at the level “to meet U.S. market demand,” FDA said.
“Until supply is restored, there are alternative therapies including the extended-release version of amphetamine mixed salts available to health care professionals and their patients for amphetamine mixed salts’ approved indications,” FDA said, advising physicians and patients to work together to “determine their best treatment option.”
Teva’s manufacturing delays were caused in part by a summer labor shortage, which has since been resolved, according to news reports.
FDA reported that Epic Pharma LLC, Rhodes Pharmaceuticals LP, and SpecGX LLC are also experiencing supply issues. In addition, a National Community Pharmacists Association survey of around 8,000 pharmacy owners and managers found that roughly 80% of small pharmacies reported having difficulty obtaining Adderall in 2022. of around 8,000 pharmacy owners and managers found that roughly 80% of small pharmacies reported having difficulty obtaining Adderall in 2022.
Physicians can check the availability of Adderall and alternative product strengths on FDA’s drug shortage
webpage.
Last Updated On
October 31, 2022
Originally Published On
October 31, 2022
Alisa Pierce
Reporter, Division of Communications and Marketing
(512) 370-1469